2022 spells change for EU pharmaceutical legislation
European Pharmaceutical Review
JUNE 24, 2022
This means numerous key aspects of how pharmaceuticals are regulated in the EU could be affected, from costing and reimbursement to intellectual property rights, incentives and more. Stakeholders in the EU often use the risk-adjusted Net Present Value (rNPV) investment model to determine whether to invest in a pharmaceutical product.
99 
Let's personalize your content